The Big Pharma disappoints investors with a weak first quarter and a failure to come to any decisions about the future structuring of the company. Meanwhile, the company made little progress of note during the quarter.
Pfizer Inc. has not started off 2013 in a strong position with first quarter earnings that disappointed analysts and investors. The world’s largest pharmaceutical company is still pondering how best to structure its massive business as it continues to show signs of wear from generic competition.
The New York-based pharma reported a 9% decline in revenues in the first quarter to $13.5 billion; the operational loss is largely attributed to the 55% drop in Lipitor (atorvastatin)...
Research would include initiatives on reproducing industry-sponsored studies, postmarket surveillance, and studies of long-term neurodevelopmental and metabolic outcomes for commonly prescribed pediatric drugs.
The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.
In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.
